Reported
Revenue (Apr 1–18)
7.66 CrINR
14 invoices · Partial period only
Calculated
Est. Gross Profit
3.16 CrINR
From standard material cost basis
Calculated
Est. Gross Margin
41.3%
API-heavy mix lifts margin
Reported
Total Volume
1,992kg
Across 8 products, 6 customers
Reported
Avg Invoice Value
54.7L INR
Per invoice average
Reported
Domestic Share
53.1%
Export: 46.9%
Reported
Export Share
46.9%
Europe + Middle East + North America
Reported
Top Customer
Asterion Pharma
1.56 Cr INR (20.4% of revenue)
Unavailable
EBITDA
—
No opex / overhead data supplied
Unavailable
Cash & Bank
—
No cash position data supplied
Unavailable
Receivables
—
No ageing / collections data supplied
Unavailable
Budget Variance
—
No budget / target data supplied
Executive Commentary
April is partially reported (1–18 Apr) with ₹7.66 Cr revenue across 14 invoices. The product mix is heavily skewed toward APIs (75.9%), which drives a healthy estimated gross margin of 41.3% — well above intermediate-level benchmarks. Asterion Pharma GmbH is the dominant customer at ₹1.56 Cr, followed by Zenith Formulations at ₹1.68 Cr combined across two invoices. Domestic markets edge out export slightly (53% vs 47%), with K. Patel owning the largest revenue book via two export accounts. No cost, receivable, inventory, or budget data is present — EBITDA, cash, and variance KPIs remain unavailable. Action required: (1) Close April sales and supply cost/opex data for margin validation; (2) Provide receivables ageing to assess working-capital risk; (3) Share monthly budget to enable variance analysis.